This forum is for the discussion of anything to do with Prostate Cancer. There are only four rules:
No fundraisers, no commercials (although it is OK to recommend choices of treatment or medical people based on your personal research; invitations to participate in third-party surveys are also acceptable, provided there is no compensation to YANA);
No harvesting e-mail addresses for Spam;
No insults or flaming - be polite and respectful at all times and understand that there may be a variety of points of view, all of which may have some validity;
Opinions are OK, but please provide as much factual evidence as possible for any assertions that you are making
Failure to abide by these simple rules will result in the immediate and permanent suspension of your posting privileges.
Since this is an International Forum, please specify your location in your post.
Re: Re: There is no treatment for localized disease
(site name for those who can read dutch)
I don't know the history, but it might help in high Gleason cases. However Taxotere is a pretty heavy deal when you are at the beginning of the road.
This can also work (see below). I have experience with one patient who became hormone refractory. He had nearly side effects on this regime and it postponed Taxotere for 2 years.
You could discuss this with your doctor
Metronomic therapy with cyclophosphamide and dexamethasone for prostate
carcinoma.Glode LM, Barqawi A, Crighton F, Crawford ED, Kerbel R.
Oncology Urology Department, University of Colorado Health Sciences Center,
Denver, Colorado 80262, USA. firstname.lastname@example.org
BACKGROUND: The current study was designed to evaluate the efficacy and
toxicity of the continuous oral administration of a combination of
cyclophosphamide (50 mg/day given in the morning) and dexamethasone (1
mg/day given in the evening) in patients with prostate specific antigen
(PSA) progression despite single or multiagent hormone therapy and
antiandrogen withdrawal. METHODS: The authors retrospectively evaluated the
medical records of all patients with prostate carcinoma who were treated
with dexamethasone and cyclophosphamide and who were unable to participate
in Phase II drug trials or had failed previous chemotherapy regimens.
RESULTS: Using clinical response guidelines set forth by the Prostate
Specific Antigen Working Group, 29% of patients were found to have a > or =
80% reduction in PSA, 39% were found to have a 50-79% reduction in PSA, 6%
were found to have a < 50% decrease in PSA, and 26% experienced disease
progression while receiving treatment. The duration of response was 8 months
(95% confidence interval [95% CI], 4-10 months). The duration of treatment
was 9 months (95% CI, 6-14 months). The treatment was reported to be well
tolerated with side effects being primarily bruising, Cushingoid facies, and
gastrointestinal distress. CONCLUSIONS: In the current study, low-dose
dexamethasone and cyclophosphamide demonstrated efficacy as salvage therapy
in the treatment of patients with hormone-refractory prostate carcinoma.
Copyright 2003 American Cancer Society.
PMID: 14534880 [PubMed - indexed for MEDLINE]
--- --- --- --- --- --- --- --- ---
Do you think there is any value in giving high risk patients(grade 3) chemotherapy taxotere immediately after prostate removal, appartently there are several trials taken place at the moment to see if this cuts the risk of cancer returning.
The only caveate I would raise re: WW is to pay attention to the slope...the rate of increase...of PSA readings. My was pretty significant (3.4 to 8.8 in just over a year) so I opted to take action. My first reading after PBRT is 0.77.
But that is not the reason I am posting today. The following is from the electronic edition of the Gainesville (FL) Sun:
New hope for fighting cancer
By Diane Chun Sun staff writer
You might describe Dr. Jorge Galante as the ultimate educated medical consumer.
The 73-year-old orthopedic surgeon has been dealing with prostate cancer for a decade. After two years of conventional treatment, including surgery and radiation, his cancer recurred.
The Chicago resident went searching for an alternative to undergoing more of the same treatment.
His search brought him to a clinical trial involving immunotherapy now under way at Shands at the University of Florida, under the direction of Dr. Johannes Vieweg, professor and chairman of the department of urology.
Galante flies to Florida once a week to receive an injection of an experimental vaccine that enlists his body's own cells in the battle against cancer.
Every year, 230,000 men are diagnosed with prostate cancer. The American Cancer Society estimates that Florida will rank behind only California and Texas in the number of new cases diagnosed this year.
Vieweg brought his studies of the potential prostate cancer vaccine with him from Duke University when he joined the UF College of Medicine faculty in 2006.
He says the customized therapy overcomes many of the obstacles and side effects of other forms of cancer treatment because it uses the patient's own cells.
Blood is drawn from the patient and the dendritic cells are isolated from the white blood cells. They are then genetically manipulated to detect the antigens that mark tumor cells before being reinjected into the patient.
Antigens are protein fragments produced by invaders such as viruses or bacteria that trigger an attack by the immune system. Vieweg characterizes them as "a red flag" at the surface of tumor cells.
The antigen telomerase is overexpressed in prostate cancer and other human cancers, Vieweg explained.
Dendritic cells activate the immune system by capturing the antigen - in this case, telomerase - and presenting it to the body's killer cells, called T cells.
The custom-made vaccine is prepared in a $4 million "clean room" in the UF Cancer and Genetics Research Building. It's not a vaccine in the traditional sense. A patient can't get a shot or two and prevent cancer. But it does enlist the body's immune system to battle against cancerous cells.
"We have something unique here," Vieweg said.
Because the dendritic cells can be programmed to seek out tumor cells with pinpoint accuracy, they can combat cancer without causing further harm to the body, unlike radiation or chemotherapy.
The strategy being tested in the current clinical trial is not limited to prostate or kidney cancer, but is potentially applicable to all cancers, in Vieweg's view.
"We just haven't done the studies to determine which forms of cancer respond best to this therapy," the researcher said. "I'd have to say we're almost there."
"Almost there" is close enough for Galante.
As part of the clinical trial, Galante is helping to prove that the vaccine is safe and effective for use by others.
But for him, the immediate benefit is that he is able to lead a normal life.
"I have a wife, children and four grandchildren whom I want to see grow up," Galante said. "I have been waiting for this vaccine to come on line."
Diane Chun can be reached at 352-374-5041 or chund@gvillesun